MDxHealth SA (NASDAQ:MDXH) Sees Significant Increase in Short Interest

MDxHealth SA (NASDAQ:MDXH) was the target of a significant increase in short interest in March. As of March 13th, there was short interest totaling 39,057 shares, an increase of 129.3% from the February 26th total of 17,033 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average trading volume of 99,293 shares, the days-to-cover ratio is presently 0.4 days.

Analysts Set New Price Targets

Several brokerages have issued reports on MDXH. Weiss Ratings reiterated a “sell (d-)” rating on shares of MDxHealth in a report on Monday, December 29th. BTIG Research reaffirmed a “buy” rating and issued a $7.00 price target on shares of MDxHealth in a report on Tuesday, December 23rd. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.75.

MDxHealth Price Performance

Shares of NASDAQ MDXH opened at $2.44 on Friday. The company has a market capitalization of $120.78 million, a P/E ratio of -3.64 and a beta of 1.61. The company has a 50 day simple moving average of $3.44 and a 200-day simple moving average of $3.74. MDxHealth has a 1 year low of $1.36 and a 1 year high of $5.33.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.04). The company had revenue of $29.55 million during the quarter, compared to analysts’ expectations of $26.05 million. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. As a group, research analysts expect that MDxHealth will post -1.15 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Intesa Sanpaolo Wealth Management purchased a new position in shares of MDxHealth during the fourth quarter worth $36,000. GSA Capital Partners LLP acquired a new stake in shares of MDxHealth in the third quarter valued at $48,000. Lido Advisors LLC acquired a new position in MDxHealth during the 3rd quarter worth about $48,000. Citadel Advisors LLC lifted its stake in MDxHealth by 30.6% during the 3rd quarter. Citadel Advisors LLC now owns 48,938 shares of the company’s stock worth $228,000 after acquiring an additional 11,456 shares in the last quarter. Finally, Jefferies Financial Group Inc. acquired a new position in MDxHealth during the 3rd quarter worth about $53,000.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.